Significant Regulatory Milestone: Vanda's HETLIOZ® Hearing on Jet Lag Disorder Approved by the FDA

Vanda Pharmaceuticals and the FDA Hearing for HETLIOZ®

In an unprecedented turn of events, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has received a formal nod from the U.S. Food and Drug Administration (FDA) to hold a hearing regarding its drug application for HETLIOZ® (tasimelteon) aimed at treating jet lag disorder. This monumental decision was communicated in a letter from the Office of the Commissioner on March 2, 2026, and represents the first such hearing in over four decades following a continuing inquiry into the effectiveness of drugs aimed at this common condition.

A Historic Hearing

The proposed evidentiary hearing arises after the FDA initially presented a proposal to deny Vanda's supplemental new drug application (sNDA). The rarity of such a formal public hearing under 21 CFR Part 12 highlights the significance of the scientific and regulatory issues at stake. Historically, the FDA has not conducted a hearing of this nature for decades, emphasizing the gravity and complexity of the discussions surrounding Vanda's application.

Dr. Mihael H. Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, expressed optimism regarding this development. He noted, “We are encouraged by the FDA's decision to grant a formal evidentiary hearing on the proposed refusal of our jet lag application for HETLIOZ®. This procedural victory reflects Vanda's 7-year persistence in advocating for fairness and the rigorous pursuit of scientific truth on behalf of patients.”

The Journey of HETLIOZ®

Currently, HETLIOZ® is approved for treating Non-24-Hour Sleep-Wake Disorder and nighttime disturbances associated with Smith-Magenis Syndrome. The current application seeks to extend its indication to jet lag disorder, a condition that affects millions of individuals globally including professional athletes, business travelers, and military personnel, yet lacks an FDA-approved therapeutic solution.

The approval for the hearing follows a notable legal victory for Vanda in the case Vanda Pharmaceuticals Inc. v. FDA, where the U.S. Court of Appeals for the D.C. Circuit nullified FDA's earlier refusal to sanction HETLIOZ® for jet lag disorder. The court's ruling underscored the FDA’s inadequate engagement with Vanda's substantial clinical evidence, which demonstrated statistically significant results benefiting patients.

Implications for the Future

This upcoming hearing stands as a critical juncture in the ongoing discourse about drug approval processes, echoing the need for transparency and accountability in regulatory decisions. It signals to the pharmaceutical industry that the FDA is willing to reassess its approaches, particularly in light of substantial evidence provided by companies.

Vanda Pharmaceuticals is dedicated to enriching the lives of patients through the development of innovative therapies, and its ongoing efforts with HETLIOZ® demonstrate their commitment to addressing unmet medical needs.

Stay tuned for further updates as the formal hearing progresses, which will not only shed light on HETLIOZ®'s future but also set important precedents for drug approvals in the healthcare landscape.

For more details about Vanda Pharmaceuticals and its products, please visit Vanda Pharmaceuticals' website or follow them on X @vandapharma.